Loading organizations...
§ Private Profile · San Francisco, CA, USA
AI-driven SaaS platform for health plans and providers, analyzing patient data to optimize medication therapy and reduce overall care costs.
Based in San Francisco, California, Arine is a healthcare technology company providing an artificial intelligence-driven medication intelligence platform to optimize drug therapy and reduce overall care costs. The B2B SaaS platform currently manages over 25 million patient lives across more than 40 health plan clients, generating upwards of 33 million clinical recommendations. By analyzing clinical, social, and behavioral data, the software helps providers and accountable care organizations reduce hospitalizations by over 40 percent and achieve greater than 10 percent savings in total care costs. The enterprise has raised more than $40 million in total funding, including a $29 million Series B round backed by institutional investors such as Ascension Ventures, 1199SEIU Health Care Employees Pension Fund, Katalyst Ventures, and Magellan Health. Arine was officially founded in 2017 by co-founders Yoona Kim and Penjit Moorhead.
Arine has raised $91.0M across 4 funding rounds.
Arine has raised $91.0M in total across 4 funding rounds.
Arine has raised $91.0M across 4 funding rounds. Most recently, it raised $30.0M Series C in May 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2025 | $30M Series C | Town Hall Ventures | 111° West Capital, Visionaire Ventures, Kaiser Permanente Ventures | Announced |
| Aug 1, 2022 | $29M Series B | 111° West Capital | Town Hall Ventures, Visionaire Ventures, Katalyst Ventures, MBX Capital, NEW Leaf Venture Partners | Announced |
| Jul 1, 2022 | $21M Series B | — | 111° West Capital, Town Hall Ventures, Visionaire Ventures | Announced |
| Jan 1, 2021 | $11M Series A | 111° West Capital, Katalyst Ventures | Town Hall Ventures, Visionaire Ventures, Magellan Health, Sachin Jain | Announced |
Arine has raised $91.0M in total across 4 funding rounds.
Arine's investors include Town Hall Ventures, 111° West Capital, Visionaire Ventures, Kaiser Permanente Ventures, Katalyst Ventures, MBX Capital, New Leaf Venture Partners, Magellan Health, Sachin Jain.
# Arine: High-Level Overview
Arine is an AI-driven SaaS platform company that optimizes medication therapy for complex patient populations across health plans and providers.[1] The company addresses a critical healthcare gap by using advanced artificial intelligence combined with clinical expertise to identify medication-related risks and recommend targeted interventions before costly health events occur.[2] Arine serves national health plans, Blues plans, and pharmacy benefit managers (PBMs), helping them improve patient outcomes while reducing costs of care across Medicare, Medicaid, and Commercial populations.[4]
The problem Arine solves is substantial: medication-related problems cause approximately 275,000 deaths annually in the U.S. and cost an estimated $528 billion—roughly $1 out of every $6 spent on healthcare.[2][4] Arine's platform integrates clinical, behavioral, and social data to deliver personalized medication recommendations at scale. The company has demonstrated remarkable growth momentum, achieving a 40% reduction in hospitalizations among health plan members, a 10% decrease in total cost of care, and has touched more than 20 million lives while producing over 40 million recommendations annually with 100% client retention.[2]
# Core Differentiators
# Role in the Broader Tech Landscape
Arine operates at the intersection of three powerful healthcare trends: the shift toward value-based care, the adoption of AI in clinical decision support, and the urgent need to address medication safety and adherence at scale. Health systems and payers face mounting pressure to improve quality metrics (Star ratings) while controlling costs, creating strong demand for intelligent medication optimization tools.[2]
The company's recognition as the 5th fastest-growing company in the AI category on Inc.'s 2024 5000 list (ranking 236 overall) reflects broader investor confidence in AI-driven healthcare solutions.[2] Arine's success demonstrates that healthcare organizations are increasingly willing to adopt sophisticated AI platforms when they deliver measurable ROI and clinical outcomes. By helping payers and providers transition from reactive to proactive medication management, Arine influences how the healthcare industry approaches population health and value-based care delivery.
# Quick Take & Future Outlook
Arine is well-positioned to expand its influence as healthcare organizations accelerate their shift toward AI-enabled, data-driven care models. The company's $66 million in funding and 100% client retention rate suggest strong product-market fit and customer satisfaction.[7] Future growth will likely depend on deepening integrations with electronic health records and expanding into adjacent areas of clinical decision support beyond medication management.
The broader healthcare ecosystem increasingly recognizes that medication optimization is foundational to improving outcomes and reducing costs. As regulatory pressure on quality metrics intensifies and payers seek competitive advantages, Arine's ability to deliver measurable improvements in adherence, hospitalizations, and cost positions it as a critical infrastructure layer in modern healthcare delivery.